Araris Biotech AG is a Swiss-headquartered company pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs.

Its linker platform enables the attachment of any drug payload to ‘off the shelf’ antibodies, without the need for prior antibody engineering.
The resulting ADCs have shown very high activity at low doses and an improved therapeutic index compared to multiple FDA-approved ADCs. Araris is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich.

At Bio-Europe, we chatted with Philipp Spycher, chief executive officer of Araris Biotech.

➡ Subscribe to our newsletter: https://bit.ly/3kHyfKc
➡ Get more biotech news:
Official site: https://bit.ly/3OJgYzi
Linkedin:   / 5312453  
Twitter:   / labiotech_eu  
Facebook:   / labiotech.eu  
Instagram:   / labiotech.eu  

About Labiotech.eu:
Labiotech.eu is an online publication covering the global biotech industry, with a mix of news and in-depth analysis. Updated daily, the site also includes a weekly podcast.

#biotech #adc #antibodydrugconjugates